Syntara Limited (ASX:SNT) Announces Positive Phase 2 Trial Results

Interim Data Highlights

Syntara Limited (ASX:SNT) reports positive interim data from its Phase 2 clinical trial evaluating SNT-5505, in combination with ruxolitinib (RUX), for myelofibrosis (MF). The interim results suggest SNT-5505 may serve as a breakthrough therapy, with data being presented at the 66th American Society of Hematology annual meeting. Significant findings include a 46% improvement in Total Symptom Score at 12 weeks, rising to 80% at 38 weeks of treatment. Additionally, 30% of evaluable patients achieved a clinically meaningful reduction in spleen volume.

Patient Outcomes and Safety Profile

The open-label study has enrolled 16 patients with high-risk MF, highlighting promising efficacy as the treatment progresses. Of note, 82% of patients experienced stable or reduced spleen volume, with significant improvements continuing over the duration of the trial. Importantly, SNT-5505 demonstrated an excellent safety profile, with no serious adverse events observed during the interim stage, underscoring its potential as a safe treatment option compared to existing MF therapies.

Executive Insight

Syntara CEO Gary Phillips stated, “A well tolerated drug that produces increasing and durable benefit the longer patients stay on is an exciting prospect.” He emphasised the importance of these interim findings, as they reflect potential superiority over other medications in this patient population. Professor Claire Harrison also commented on the data’s implications for long-term benefits, reinforcing the significance of SNT-5505’s mechanism in addressing the disease’s challenges.

Future Plans

Syntara plans to release further interim data in early 2025 and final data later in the year. Following a subset of patients reaching 52 weeks of treatment, the company aims to discuss trial design for a pivotal Phase 2c/3 study with the FDA. The ongoing engagement with global and regional partners is also on the agenda to further advance SNT-5505’s development.

View Original Announcement

here

Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Syntara. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.